Drugs for autoimmune inflammatory diseases: From small molecule compounds to anti-TNF biologics

Frontiers in Pharmacology

Volumn 8, Issue JUL, 2017, Pages

  Li, Ping ^a   Zheng, Ying ^a   Chen, Xin ^a  

^a University of Macau   (Macao)

Author keywords

Anti TNF biologics; Autoimmune inflammatory diseases; Non steroidal anti inflammatory drugs (NSAIDs); TNF receptor; Tumor necrosis factor alpha (TNF)

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; BETAMETHASONE; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CORTISONE; CYCLOSPORIN; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLUFENAMIC ACID; GLUCOCORTICOID; GOLIMUMAB; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; MECLOFENAMIC ACID; MEFENAMIC ACID; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PREDNISOLONE; PREDNISONE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CONGESTIVE HEART FAILURE; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INTESTINE PERFORATION; INTESTINE ULCER; NEPHROTOXICITY; PAIN; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SUDDEN CARDIAC DEATH; ULCERATIVE COLITIS;

EID: 85025440000     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00460     Document Type: Review

References (146)

1. Aggarwal, B. B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745-756. doi: 10.1038/nri1184
2. Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., and Taubert, K. A. (2007). Use of nonsteroidal Antiinflammatory drugs an update for clinicians-A scientific statement from the American Heart Association. Circulation 115, 1634-1642. doi: 10.1161/Circulationaha.106.181424
3. Antoni, C., and Braun, J. (2002). Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20(6 Suppl. 28), S152-S157.
4. Atzeni, F., Turiel, M., Capsoni, F., Doria, A., Meroni, P., and Sarzi-Puttini, P. (2005). Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 1051, 559-569. doi: 10.1196/annals.1361.100
5. Balakumar, P., and Singh, M. (2006). Anti-tumour necrosis factor-alpha therapy in heart failure: future directions. Basic Clin. Pharmacol. Toxicol. 99, 391-397. doi: 10.1111/j.1742-7843.2006.pto_508.x
6. Barnes, P. J. (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. 94, 557-572. doi: 10.1042/cs0940557
7. Bendix, G., and Bjelle, A. (1996). A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Ann. Rheum. Dis. 55, 169-176. doi: 10.1136/Ard.55.3.169
8. Billiau, A. (1988). Gamma-interferon: the match that lights the fire? Immunol. Today 9, 37-40. doi: 10.1016/0167-5699(88)91256-X
9. Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., et al. (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733. doi: 10.1038/385729a0
10. Boers, M., Verhoeven, A. C., Markusse, H. M., van de Laar, M. A. F. J., Westhovens, R., van Denderen, J. C., et al. (1997). Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350, 309-318. doi: 10.1016/S0140-6736(97)01300-7
11. Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., and Montori, V. (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285. doi: 10.1001/jama.295.19.2275
12. Box, S. A., and Pullar, T. (1997). Sulphasalazine in the treatment of rheumatoid arthritis. Br. J. Rheumatol. 36, 382-386. doi: 10.1093/rheumatology/36.3.382
13. Bragazzi, N. L., Watad, A., Brigo, F., Adawi, M., Amital, H., and Shoenfeld, Y. (2016). Public health awareness of autoimmune diseases after the death of a celebrity. Clin. Rheumatol. doi: 10.1007/s10067-016-3513-5 [Epub ahead of print].
14. Busson, M. (1986). Update on ibuprofen: review article. J. Int. Med. Res. 14, 53-62. doi: 10.1177/030006058601400201
15. Buttgereit, F., Burmester, G. R., Straub, R. H., Seibel, M. J., and Zhou, H. (2011). Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 63, 1-9. doi: 10.1002/art.30070
16. Campa, M., Mansouri, B., Warren, R., and Menter, A. (2016). A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol. Ther. 6, 1-12. doi: 10.1007/s13555-015-0092-3
17. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 72, 3666-3670. doi: 10.1073/pnas.72.9.3666
18. Chatzantoni, K., and Mouzaki, A. (2006). Anti-TNF-alpha antibody therapies in autoimmune diseases. Curr. Top. Med. Chem. 6, 1707-1714. doi: 10.2174/156802606778194217
19. Chen, W., Xu, H., Wang, X., Gu, J., Xiong, H., and Shi, Y. (2015). The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: a meta-analysis. Int. Immunopharmacol. 28, 146-153. doi: 10.1016/j.intimp.2015.05.049
20. Chen, X., Baumel, M., Mannel, D. N., Howard, O. M., and Oppenheim, J. J. (2007). Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 179, 154-161. doi: 10.4049/jimmunol.179.1.154
21. Chen, X., Murakami, T., Oppenheim, J. J., and Howard, O. M. (2004). Differential response of murine CD4+CD25+ and CD4+CD25-T cells to dexamethasone-induced cell death. Eur. J. Immunol. 34, 859-869. doi: 10.1002/eji.200324506
22. Chen, X., Nie, Y., Xiao, H., Bian, Z., Scarzello, A. J., Song, N. Y., et al. (2016). TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. Sci. Rep. 6:32834. doi: 10.1038/srep32834
23. Chen, X., and Oppenheim, J. J. (2011). Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 585, 3611-3618. doi: 10.1016/j.febslet.2011.04.025
24. Chen, X., and Oppenheim, J. J. (2016). Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity. Nat. Rev. Rheumatol. 12, 625-626. doi: 10.1038/nrrheum.2016.145
25. Chen, X., Oppenheim, J. J., Winkler-Pickett, R. T., Ortaldo, J. R., and Howard, O. M. (2006). Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur. J. Immunol. 36, 2139-2149. doi: 10.1002/eji.200635873
26. Chen, X., Subleski, J. J., Hamano, R., Howard, O. M., Wiltrout, R. H., and Oppenheim, J. J. (2010). Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur. J. Immunol. 40, 1099-1106. doi: 10.1002/eji.200940022
27. Chen, X., Subleski, J. J., Kopf, H., Howard, O. M., Mannel, D. N., and Oppenheim, J. J. (2008). Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J. Immunol. 180, 6467-6471. doi: 10.4049/jimmunol.180.10.6467
28. Chen, X., Willette-Brown, J., Wu, X., Hu, Y., Howard, O. M., Hu, Y., et al. (2015). IKKalpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells. FASEB J. 29, 443-454. doi: 10.1096/fj.14-259564
29. Chen, X., Wu, X. Q., Zhou, Q., Howard, O. M. Z., Netea, M. G., and Oppenheim, J. J. (2013). TNFR2 Is critical for the stabilization of the CD4(+)Foxp3(+) regulatory T cell phenotype in the inflammatory environment. J. Immunol. 190, 1076-1084. doi: 10.4049/jimmunol.1202659
30. Cheng, D. S., and Visco, C. J. (2012). Pharmaceutical therapy for osteoarthritis. PM R 4(5 Suppl.), S82-S88. doi: 10.1016/j.pmrj.2012.02.009
31. Choy, E. H., Hazleman, B., Smith, M., Moss, K., Lisi, L., Scott, D. G., et al. (2002). Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41, 1133-1137. doi: 10.1093/rheumatology/41.10.1133
32. Coley, W. B. (1891). II. Contribution to the Knowledge of Sarcoma. Ann. Surg. 14, 199-220.
33. Cooper, G. S., Bynum, M. L., and Somers, E. C. (2009). Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 33, 197-207. doi: 10.1016/j.jaut.2009.09.008
34. Costedoat-Chalumeau, N., Dunogue, B., Leroux, G., Morel, N., Jallouli, M., Le Guern, V., et al. (2015). A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin. Rev. Allergy Immunol. 49, 317-326. doi: 10.1007/s12016-015-8469-8
35. Crofford, L. J. (1997). COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. Suppl. 49, 15-19.
36. Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., et al. (2006). Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 55, 420-426. doi: 10.1002/art.21984
37. Dajani, E. Z., and Islam, K. (2008). Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J. Physiol. Pharmacol. 59, 117-133.
38. Deeks, E. D. (2016). Certolizumab pegol: a review in inflammatory autoimmune diseases. BioDrugs 30, 607-617. doi: 10.1007/s40259-016-0197-y
39. Desai, R. J., Hansen, R. A., Rao, J. K., Wilkins, T. M., Harden, E. A., Yuen, A., et al. (2012). Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. Ann. Pharmacother. 46, 1491-1505. doi: 10.1345/aph.1R203
40. Dorner, T., and Kay, J. (2015). Biosimilars in rheumatology: current perspectives and lessons learnt. Nat. Rev. Rheumatol. 11, 713-724. doi: 10.1038/nrrheum.2015.110
41. Dorner, T., Strand, V., Cornes, P., Goncalves, J., Gulacsi, L., Kay, J., et al. (2016). The changing landscape of biosimilars in rheumatology. Ann. Rheum. Dis. 75, 974-982. doi: 10.1136/annrheumdis-2016-209166
42. Efimov, G. A., Kruglov, A. A., Tillib, S. V., Kuprash, D. V., and Nedospasov, S. A. (2009). Tumor necrosis factor and the consequences of its ablation in vivo. Mol. Immunol. 47, 19-27. doi: 10.1016/j.molimm.2009.01.007
43. Ellis, J. S., and Braley-Mullen, H. (2017). Mechanisms by which B cells and regulatory t cells influence development of murine organ-specific autoimmune diseases. J. Clin. Med. 6:13. doi: 10.3390/jcm6020013
44. Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., et al. (2008). Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375-382. doi: 10.1016/S0140-6736(08)61000-4
45. Ethgen, O., Esteves, F. D., Bruyere, O., and Reginster, J. Y. (2013). What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr. Med. Res. Opin. 29, 1147-1160. doi: 10.1185/03007995.2013.818531
46. Fang, F. C. (1997). Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 99, 2818-2825. doi: 10.1172/JCI119473
47. Faustman, D., and Davis, M. (2010). TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482-493. doi: 10.1038/nrd3030
48. Favalli, E. G., Biggioggero, M., and Meroni, P. L. (2014). Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun. Rev. 13, 1102-1108. doi: 10.1016/j.autrev.2014.08.026
49. Feldmann, M., Brennan, F. M., and Maini, R. N. (1996). Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440. doi: 10.1146/annurev.immunol.14.1.397
50. Ferreira, J. F., Ahmed Mohamed, A. A., and Emery, P. (2016). Glucocorticoids and rheumatoid arthritis. Rheum. Dis. Clin. North Am. 42, 33-46, vii. doi: 10.1016/j.rdc.2015.08.006
51. Fiorino, G., and Danese, S. (2014). The biosimilar road in inflammatory bowel disease: the right way? Best Pract. Res. Clin. Gastroenterol. 28, 465-471. doi: 10.1016/j.bpg.2014.04.006
52. Fleischmann, R. A. (2009). Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin. Arthritis Rheum. 38, 265-280. doi: 10.1016/j.semarthrit.2008.01.001
53. Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G. R., Tesser, J., et al. (2003). Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis-A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48, 927-934. doi: 10.1002/art.10870
54. Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., et al. (1999). Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 93, 198-208. doi: 10.1006/clim.1999.4777
55. Frey, F. J. (1987). Kinetics and dynamics of prednisolone. Endocr. Rev. 8, 453-473. doi: 10.1210/edrv-8-4-453
56. Fujita, T., Kutsumi, H., Sanuki, T., Hayakumo, T., and Azuma, T. (2013). Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug-or low-dose aspirin-induced gastrointestinal injuries. J. Gastroenterol. 48, 559-573. doi: 10.1007/s00535-013-0771-8
57. Gabriel, S. E., Coyle, D., and Moreland, L. W. (2001). A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 19, 715-728. doi: 10.2165/00019053-200119070-00002
58. Genovese, M. C., Becker, J. C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., et al. (2005). Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353, 1114-1123. doi: 10.1056/NEJMoa050524
59. Gerhardt, M. C. (1853). X.-Researches on the constitution of organic acids. Q. J. Chem. Soc. 5, 127-131. doi: 10.1039/QJ8530500127
60. Gerland, H. (1853). XII.-New formation of salicylic acid. Q. J. Chem. Soc. 5, 133-136. doi: 10.1039/QJ8530500133
61. Gibellini, L., De Biasi, S., Bianchini, E., Bartolomeo, R., Fabiano, A., Manfredini, M., et al. (2016). Anti-TNF-alpha drugs differently affect the TNFalpha-sTNFR system and monocyte subsets in patients with psoriasis. PLoS ONE 11:e0167757. doi: 10.1371/journal.pone.0167757
62. Glyn, J. (1998). The discovery and early use of cortisone. J. R. Soc. Med. 91, 513-517. doi: 10.1177/014107689809101004
63. Govindaraj, C., Scalzo-Inguanti, K., Scholzen, A., Li, S., and Plebanski, M. (2013). TNFR2 expression on CD25(hi)FOXP3(+) T cells induced upon TCR stimulation of CD4 T cells identifies maximal cytokine-producing effectors. Front. Immunol. 4:233. doi: 10.3389/fimmu.2013.00233
64. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., et al. (1995). The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802. doi: 10.1016/0092-8674(95)90192-2
65. Grosser, T., Fries, S., and FitzGerald, G. A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15. doi: 10.1172/JCI27291
66. Guerra, I., Algaba, A., Perez-Calle, J. L., Chaparro, M., Marin-Jimenez, I., Garcia-Castellanos, R., et al. (2012). Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J. Crohns Colitis 6, 518-523. doi: 10.1016/j.crohns.2011.10.007
67. Hedner, T., and Everts, B. (1998). The early clinical history of salicylates in rheumatology and pain. Clin. Rheumatol. 17, 17-25. doi: 10.1007/BF01450953
68. Hench, P. S., and Kendall, E. C., Slocumb, C. H., and Polley, H. F. (1949). The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181-197.
69. Hermann, M., and Ruschitzka, F. (2006). Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern. Med. J. 36, 308-319. doi: 10.1111/j.1445-5994.2006.01056.x
70. Hoffmann, W., and Förster, W. (1987). Two years follow-up Cottbus reinfarction study with 30 and 60 mg acetylsalicylic acid. Prog. Clin. Biol. Res. 242, 393-397.
71. Ioannidis, J. P. A., Karassa, F. B., Druyts, E., Thorlund, K., and Mills, E. J. (2013). Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat. Rev. Rheumatol. 9, 665-673. doi: 10.1038/nrrheum.2013.134
72. Jang, C. H., Choi, J. H., Byun, M. S., and Jue, D. M. (2006). Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 45, 703-710. doi: 10.1093/rheumatology/kei282
73. Kalden, J. R., Antoni, C., Alvaro-Gracia, J. M., Combe, B., Emery, P., Kremer, J. M., et al. (2005). Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J. Rheumatol. 32, 1620-1631.
74. Kang, Y., Xu, L., Wang, B., Chen, A., and Zheng, G. (2008). Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. J. Immunol. 180, 5172-5176. doi: 10.4049/jimmunol.180.8.5172
75. Karanikolas, G., Charalambopoulos, D., Andrianakos, A., Antoniades, C., and Katsilambros, N. (2006). Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J. Rheumatol. 33, 486-489.
76. Kerensky, T. A., Gottlieb, A. B., Yaniv, S., and Au, S. C. (2012). Etanercept: efficacy and safety for approved indications. Expert Opin. Drug Saf. 11, 121-139. doi: 10.1517/14740338.2012.633509
77. Kersley, G. D. (1968). Amethopterin (methotrexate) in connective tissue disease-psoriasis and polyarthritis. Ann. Rheum. Dis. 27, 64-66. doi: 10.1136/ard.27.1.64
78. Keystone, E., van der Heijde, D., Mason, D., Landewe, R., van Vollenhoven, R., Combe, B., et al. (2008). Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319-3329. doi: 10.1002/art.23964
79. Khanapure, S. P., Garvey, D. S., Young, D. V., Ezawa, M., Earl, R. A., Gaston, R. D., et al. (2003). Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. J. Med. Chem. 46, 5484-5504. doi: 10.1021/jm030268b
80. Kim, S. C., Yelin, E., Tonner, C., and Solomon, D. H. (2013). Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the united states during 1983-2009. Arthritis Care Res. 65, 1529-1533. doi: 10.1002/acr.21997
81. Koutruba, N., Emer, J., and Lebwohl, M. (2010). Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther. Clin. Risk Manag. 6, 123-141.
82. Kremer, J., Genovese, M., Cannon, G. W., Caldwell, J., Cush, J., Furst, D. E., et al. (2004). Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J. Rheumatol. 31, 1521-1531.
83. Laev, S. S., and Salakhutdinov, N. F. (2015). Anti-arthritic agents: progress and potential. Bioorg. Med. Chem. 23, 3059-3080. doi: 10.1016/j.bmc.2015.05.010
84. Lapadula, G., Marchesoni, A., Armuzzi, A., Blandizzi, C., Caporali, R., Chimenti, S., et al. (2014). Adalimumab in the treatment of immune-mediated diseases. Int. J. Immunopathol. Pharmacol. 27(1 Suppl.), 33-48. doi: 10.1177/03946320140270S103
85. Lasry, A., Zinger, A., and Ben-Neriah, Y. (2016). Inflammatory networks underlying colorectal cancer. Nat. Immunol. 17, 230-240. doi: 10.1038/ni.3384
86. Lowenberg, M., and D'Haens, G. (2013). Novel targets for inflammatory bowel disease therapeutics. Curr. Gastroenterol. Rep. 15:311. doi: 10.1007/s11894-012-0311-3
87. Mauritz, N. J., Holmdahl, R., Jonsson, R., Van der Meide, P. H., Scheynius, A., and Klareskog, L. (1988). Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum. 31, 1297-1304. doi: 10.1002/art.1780311012
88. Mazumdar, S., and Greenwald, D. (2009). Golimumab. MAbs 1, 422-431. doi: 10.4161/mabs.1.5.9286
89. McCann, F. E., Perocheau, D. P., Ruspi, G., Blazek, K., Davies, M. L., Feldmann, M., et al. (2014). Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 66, 2728-2738. doi: 10.1002/art.38755
90. Meier, F. M. P., Frerix, M., Hermann, W., and Muller-Ladner, U. (2013). Current immunotherapy in rheumatoid arthritis. Immunotherapy 5, 955-974. doi: 10.2217/imt.13.94
91. Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., Gonzalez-Lorenzo, M., Bastiampillai, A. J., et al. (2016). Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin. Drug Saf. 15, 11-34. doi: 10.1080/14740338.2016.1240783
92. Monaco, C., Nanchahal, J., Taylor, P., and Feldmann, M. (2015). Anti-TNF therapy: past, present and future. Int. Immunol. 27, 55-62. doi: 10.1093/intimm/dxu102
93. Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., et al. (1999). Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478-486. doi: 10.7326/0003-4819-130-6-199903160-00004
94. Moudgil, K. D., and Choubey, D. (2011). Cytokines in autoimmunity: role in induction, regulation, and treatment. J. Interferon Cytokine Res. 31, 695-703. doi: 10.1089/jir.2011.0065
95. Murray, M. D., and Brater, D. C. (1993). Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 33, 435-465. doi: 10.1146/annurev.pa.33.040193.002251
96. Nathan, D. M., Iser, J. H., and Gibson, P. R. (2008). A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J. Gastroenterol. Hepatol. 23, 954-958. doi: 10.1111/j.1440-1746.2007.05006.x
97. Neeck, G. (2002). Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann. N. Y. Acad. Sci. 966, 28-38. doi: 10.1111/j.1749-6632.2002.tb04199.x
98. Nguyen, D. X., and Ehrenstein, M. R. (2016). Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J. Exp. Med. 213, 1241-1253. doi: 10.1084/jem.20151255
99. ODell, J. R., Haire, C. E., Erikson, N., Drymalski, W., Palmer, W., Eckhoff, P. J., et al. (1996). Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287-1291. doi: 10.1056/Nejm199605163342002
100. ODell, J. R., Leff, R., Paulsen, G., Haire, C., Mallek, J., Eckhoff, P. J., et al. (2002). Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications-Results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 1164-1170. doi: 10.1002/art.10228
101. Okubo, Y., Mera, T., Wang, L., and Faustman, D. L. (2013). Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci. Rep. 3:3153. doi: 10.1038/srep03153
102. Okuda, Y. (2008). Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2, 75-82. doi: 10.2147/btt.s1828
103. Osiri, M., Shea, B., Robinson, V., Suarez-Almazor, M., Strand, V., Tugwell, P., et al. (2003). Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J. Rheumatol. 30, 1182-1190.
104. Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., and Moldawer, L. L. (2003). Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2, 736-746. doi: 10.1038/nrd1175
105. Pasut, G. (2014). Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs 28(Suppl. 1), S15-S23. doi: 10.1007/s40259-013-0064-z
106. Pfeffer, K. (2003). Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 14, 185-191. doi: 10.1016/S1359-6101(03)00022-4
107. Rainsford, K. D. (2007). Anti-inflammatory drugs in the 21st century. Subcell Biochem. 42, 3-27. doi: 10.1007/1-4020-5688-5_1
108. Rau, R. (2002). Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann. Rheum. Dis. 61, 70-73. doi: 10.1136/ard.61.suppl_2.ii70
109. Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., and Griffin, M. R. (2002). COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360, 1071-1073. doi: 10.1016/S0140-6736(02)11131-7
110. Rhen, T., and Cidlowski, J. A. (2005). Antiinflammatory action of glucocorticoids-New mechanisms for old drugs. N. Engl. J. Med. 353, 1711-1723. doi: 10.1056/Nejmra050541
111. Robinson, W. H., Genovese, M. C., and Moreland, L. W. (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 44, 1977-1983. doi: 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6
112. Roda, G., Jharap, B., Neeraj, N., and Colombel, J. F. (2016). Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl. Gastroenterol. 7:e135. doi: 10.1038/ctg.2015.63
113. Sandborn, W. J., Hanauer, S., Loftus, E. V., Tremaine, W. J., Kane, S., Cohen, R., et al. (2004). An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. 99, 1984-1989. doi: 10.1111/j.1572-0241.2004.40462.x
114. Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq-Kareemi, M., Kamm, M. A., Boivin, M., et al. (2005). A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129, 807-818. doi: 10.1053/j.gastro.2005.06.064
115. Schurgers, E., Billiau, A., and Matthys, P. (2011). Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-gamma. J. Interferon Cytokine Res. 31, 917-926. doi: 10.1089/jir.2011.0056
116. Sharp, J. T., Strand, V., Leung, H., Hurley, F., and Loew-Friedrich, I. (2000). Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 43, 495-505. doi: 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U
117. Shealy, D., Cai, A., Lacy, E., Nesspor, T., Staquet, K., Johns, L., et al. (2007). Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNFalpha. Ann. Rheum. Dis. 66, 151-151.
118. Shealy, D. J., Cai, A., Staquet, K., Baker, A., Lacy, E. R., Johns, L., et al. (2010). Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2, 428-439. doi: 10.4161/mabs.12304
119. Shelton, E., Laharie, D., Scott, F. I., Mamtani, R., Lewis, J. D., Colombel, J. F., et al. (2016). Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 151, 97.e4-109.e4. doi: 10.1053/j.gastro.2016.03.037
120. Shen, T. Y. (1982). The discovery of indomethacin and the proliferation of nsaids. Semin. Arthritis Rheum. 12, 89-93. doi: 10.1016/0049-0172(82)90004-X
121. Shibata, H., Yoshioka, Y., Abe, Y., Ohkawa, A., Nomura, T., Minowa, K., et al. (2009). The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 30, 6638-6647. doi: 10.1016/j.biomaterials.2009.08.041
122. Sigidin, Y. A., Loukina, G. V., Skurkovich, B., and Skurkovich, S. (2001). Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand. J. Rheumatol. 30, 203-207. doi: 10.1080/030097401316909530
123. Silverman, E., Mouy, R., Spiegel, L., Jung, L. K., Saurenmann, R. K., Lahdenne, P., et al. (2005). Leflunomide or methotrexate for juvenile rheumatoid arthritis. N. Engl. J. Med. 352, 1655-1666. doi: 10.1056/NEJMoa041810
124. Simmons, D. L., Botting, R. M., and Hla, T. (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437. doi: 10.1124/pr.56.3.3
125. Simon, L. S. (2004). The treatment of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 18, 507-538. doi: 10.1016/j.berh.2004.04.005
126. Skosey, J. L. (1988). Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis. J. Rheumatol. Suppl. 16, 5-8.
127. Sticherling, M. (2016). Psoriasis and autoimmunity. Autoimmun. Rev. 15, 1167-1170. doi: 10.1016/j.autrev.2016.09.004
128. Swierkot, J., and Szechinski, J. (2006). Methotrexate in rheumatoid arthritis. Pharmacol. Rep. 58, 473-492.
129. Tabas, I., and Glass, C. K. (2013). Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166-172. doi: 10.1126/science.1230720
130. Taherian, E., Rao, A., Malemud, C. J., and Askari, A. D. (2013). The biological and clinical activity of anti-malarial drugs in autoimmune disorders. Curr. Rheumatol. Rev. 9, 45-62. doi: 10.2174/1573397111309010010
131. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., and Tak, P. P. (2008). Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244-279. doi: 10.1016/j.pharmthera.2007.10.001
132. Vainio, H., and Morgan, G. (1997). Aspirin for the second hundred years: new uses for an old drug. Pharmacol. Toxicol. 81, 151-152. doi: 10.1111/j.1600-0773.1997.tb02060.x
133. van de Putte, L. B., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L., et al. (2004). Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, 508-516. doi: 10.1136/ard.2003.013052
134. van Vollenhoven, R. F., Geborek, P., Forslind, K., Albertsson, K., Ernestam, S., Petersson, I. F., et al. (2012). Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379, 1712-1720. doi: 10.1016/S0140-6736(12)60027-0
135. Vandenabeele, P., Declercq, W., Beyaert, R., and Fiers, W. (1995). Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5, 392-399. doi: 10.1016/S0962-8924(00)89088-1
136. Vane, J. R. (2000). The fight against rheumatism: from willow bark to COX-1 sparing drugs. J. Physiol. Pharmacol. 51(4 Pt 1), 573-586.
137. Vila-Del Sol, V., Diaz-Munoz, M. D., and Fresno, M. (2007). Requirement of tumor necrosis factor at and nuclear factor-kappa B in the induction by IFN-gamma of inducible nitric oxide synthase in macrophages. J. Leukoc. Biol. 81, 272-283. doi: 10.1189/jlb.0905529
138. Visser, K., and van der Heijde, D. (2009). Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 68, 1094-1099. doi: 10.1136/ard.2008.092668
139. Wahl, C., Liptay, S., Adler, G., and Schmid, R. M. (1998). Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101, 1163-1174. doi: 10.1172/JCI992
140. Wallis, R. S. (2007). Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J. Invest. Dermatol. Symp. Proc. 12, 16-21. doi: 10.1038/sj.jidsymp.5650031
141. Wijnen, P. A., Cremers, J. P., Nelemans, P. J., Erckens, R. J., Hoitsma, E., Jansen, T. L., et al. (2014). Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur. Respir. J. 43, 1730-1739. doi: 10.1183/09031936.00169413
142. Willrich, M. A., Murray, D. L., and Snyder, M. R. (2015). Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl. Res. 165, 270-282. doi: 10.1016/j.trsl.2014.09.006
143. Yelamos, O., and Puig, L. (2015). Systemic methotrexate for the treatment of psoriasis. Expert Rev. Clin. Immunol. 11, 553-563. doi: 10.1586/1744666X.2015.1026894
144. Yoo, D. H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., et al. (2013). A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 72, 1613-1620. doi: 10.1136/annrheumdis-2012-203090
145. Zaragoza, B., Chen, X., Oppenheim, J. J., Baeyens, A., Gregoire, S., Chader, D., et al. (2016). Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat. Med. 22, 16-17. doi: 10.1038/nm.4019
146. Zhou, H. H., Jang, H. S., Fleischmann, R. M., Bouman-Thio, E., Xu, Z. H., Marini, J. C., et al. (2007). Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47, 383-396. doi: 10.1177/0091270006298188